InvestorsHub Logo
Followers 10
Posts 504
Boards Moderated 0
Alias Born 04/20/2016

Re: None

Tuesday, 12/29/2020 1:23:10 PM

Tuesday, December 29, 2020 1:23:10 PM

Post# of 869
$4 price target by BTIG's 5 star analyst, Robert Hazlett, helps, but it is old news.

What is more important are the reasons given by Hazlett for his $4 price target:

1. Ongoing LNC trials funded by the NIH and CF Foundation;

2. Soon to be announced results from a second head to head trial of MAT 9001 vs. Vascepa, with results expected to strongly favor MAT 9001; and

3. Collaborations with 5 big pharmaceutical companies, any one of which could choose to purchase MTNB at a huge premium for what would be a pittance for any of these companies.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent MTNB News